Fig. 5.
In vivo efficacy in mouse models of infection. a Efficacy of Lynronne-1, Lynronne-2, Lynronne-3 and mupirocin against methicillin resistant S. aureus, USA300 MRSA (BAA-1717), wound infection in, ICR mice. Inoculum = 1.05 × 105 CFU/ml. b Efficacy of Lynronne-1 and mupirocin against methicillin resistant S. aureus, USA300 MRSA (BAA-1717). c Efficacy of intravenously administered Lynronne-1, Lynronne-2, Lynronne-3 and Vancomycin in the S. aureus (ATCC 33591) MRSA thigh infection model with neutropenic male ICR mice. Inoculum = 1.57 × 105 CFU/ml, ×1 (administered once at 2 h) or ×2 (twice at 2 and 8 h post infection). *, **, *** Significant difference (P < 0.05, 0.01 and 0.001, respectively) compared to the control group (PBS or 0.9% NaCl) was determined by one-way ANOVA followed by the use of a Dunnett’s test